NEWS & PERSPECTIVES
Psychedelics News
Curated updates on microdosing, research, policy, and community.
The latest
Is Microdosing Just a Placebo? What Placebo-Controlled Studies Show
Placebo-controlled studies show that microdoses measurably change the brain and body, but so far they find few consistent improvements in mood or wellbeing beyond placebo. Surveys and personal reports are far more pos...
Altered ‘state’ vs Altered ‘sense of self’
Psychedelic culture has given us a powerful image of transformation: the self dissolves, the familiar world disappears, and somehow we return, from the other side, changed. It is the territory associated with the larg...
Citizen Science x Phenomenology
Journaling, editing, reflecting, integrating – all remain valid when formalising your anecdotal report, to make sense of everything you experienced during your protocol. But, what if the quality of your microdosing e...
Estimating Cardiac 5-HT2B Safety Margins for Repeated Low-Dose Psilocybin Using an Exposure-Response Model
This modelling study, supported by a rat experiment, assessed whether repeated low-dose psilocybin could pose a heart valve risk by acting on the 5-HT2B receptor. It found a 3 mg daily regimen had a large safety margi...
Clinical improvement following an integrative iboga microdosing protocol in post-concussive and hypoxic brain injury syndromes: a case series
In a study on iboga microdosing, in all three cases, participants reported better sleep, improved mood regulation, and a greater ability to return to daily activities.
LSD microdosing for major depressive disorder: Mood and pharmacokinetic outcomes from a Phase 2a trial
Repeated microdosing of LSD (8 to 20 μg) may help improve daily mood, specifically increasing feelings of connection, creativity, and energy in people with major depressive disorder.
It’s all about the relationship: The caregiver experience of supporting a person with advanced cancer going through an LSD microdosing trial
Caregivers of people with advanced cancer often find that psychedelic-assisted therapy can strengthen their relationships and provide a sense of hope during difficult times.
Epidemiology of Hallucinogen Microdosing Among Young Adults in the United States: A National Study
About 1 in 15 young adults in the United States reported microdosing hallucinogens in the past year.
Comparing single- and repeat-dose psilocybin with active placebo for migraine prevention in an exploratory randomized controlled clinical trial
Low doses of psilocybin may reduce the frequency of migraine attacks, but a two-dose "pulsed" schedule did not show a significant advantage over a single dose in this trial.
Microdosing psychedelics and its effect on creativity: Lessons learned from three double-blind placebo controlled longitudinal trials
Microdosing psilocybin can improve the quality of creative thinking by helping people come up with more original ideas.
What is it like to microdose LSD for depression? a thematic analysis of participant interviews from an open-label trial
Participants with major depressive disorder reported feeling more motivated, more connected to others, and better able to process emotions during an eight-week LSD microdosing trial.
Authors of Largest Microdosing Study Suggest Benefits Limited To Dosing Day
Recent research surveying 1,435 microdosers suggests that microdosing’s duration of effect might be more like that of drinking a coffee, with benefits that come and go by day’s end. The post Authors of Largest Microdo...
Participant Experiences of Microdosed Lysergic Acid Diethylamide in a 6-Week Randomised Controlled Trial
This qualitative study (n=40) of healthy males following a double-blind placebo-controlled trial of LSD microdosing (10µg every third day for 6 weeks) found participants reported effects across emotions and mood, soci...
LSD microdosing in major depressive disorder: results from an open-label trial
This open-label Phase IIa trial (n=19, 15 male) found that an 8-week regimen of microdosed LSD (8μg initially, then 6-20μg twice weekly) for major depressive disorder was well-tolerated with no serious adverse events ...
Cognitive and Subjective Effects of Psilocybin Microdosing: Results from Two Double-Blind Placebo-Controlled Longitudinal Trials
These two randomised, double-blind, placebo-controlled trials (n=141) conducted in semi-naturalistic settings found that microdosing psilocybin truffles did not significantly affect cognitive control, memory, social c...